Why Gilead Sciences’ Livdelzi data could reshape treatment goals in primary biliary cholangitis
Find out how Gilead Sciences’ Livdelzi trial data could reshape PBC treatment goals and strengthen the case for ALP normalization.
Pharma & Biotech